Ceftobiprole for the treatment of pneumonia: Aeuropean perspective

Adamantia Liapikou, Catia Cillóniz, Antonio Torres

Producción científica: Artículo CientíficoArtículo de revisiónrevisión exhaustiva

37 Citas (Scopus)


Ceftobiprole, a new broad spectrum, parenteral cephalosporin, exhibits potent in vitro activity against a number of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and Gram-negative pathogens associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). Ceftobiprole has demonstrated noninferiority in two large-scale pivotal studies comparing it to ceftriaxone with or without linezolid in CAP, with clinical cure rates 86.6% versus 87.4%, or ceftazidime in HAP, with clinical cure rates of 77% versus 76%, respectively. However, ceftobiprole was inferior in the subgroup of patients undergoing mechanical ventilation. Ceftobiprole has so far demonstrated a good safety profile in preliminary studies, with similar tolerability to comparators. The most commonly observed adverse events of ceftobiprole included headache and gastrointestinal upset. It is the first cephalosporin monotherapy approved in the EU for the treatment of both CAP and HAP (excluding ventilator-associated pneumonia).

Idioma originalInglés estadounidense
Páginas (desde-hasta)4565-4572
PublicaciónDrug Design, Development and Therapy
EstadoIndizado - 18 ago. 2015
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2015 Liapikou et al.


Profundice en los temas de investigación de 'Ceftobiprole for the treatment of pneumonia: Aeuropean perspective'. En conjunto forman una huella única.

Citar esto